Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -17.26%4 Current Ratio is 31.91 as of Mar. 2026, which is 511% above its 10-year median of 5.22. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 1,408 Biotechnology companies, BeBetter Med ranks better than 97.02% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BeBetter Med's current ratio for the quarter that ended in Mar. 2026 was 31.91.
BeBetter Med has a current ratio of 31.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BeBetter Med's Current Ratio or its related term are showing as below:
SHSE:688759'
s Current Ratio Range Over the Past 10 Years
Min: 0.73 Med: 5.22 Max: 35.95
Current: 31.91
During the past 7 years, BeBetter Med's highest Current Ratio was 35.95. The lowest was 0.73. And the median was 5.22.
SHSE:688759's Current Ratio is ranked better than 97.02% of 1408
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688759: 31.91
BeBetter Med (SHSE:688759) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BeBetter Med Current Ratio Related Terms
BeBetter Med Current Ratio Historical Data
* Premium members only.
The historical data trend for BeBetter Med's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, BeBetter Med's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's Current Ratio distribution charts can be found below:
* The bar in red indicates where BeBetter Med's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeBetter Med (SHSE:688759) has a Current Ratio of 31.91 as of Mar. 2026. This is 511% above median its historical median of 5.22. Over the past decade, BeBetter Med's Current Ratio has ranged from 0.73 to 35.95. According to the industry distribution chart, BeBetter Med ranks #42 out of 1408 companies in the Biotechnology industry, placing it in the top 3%.
Is BeBetter Med's Current Ratio too high?
BeBetter Med's current Current Ratio of 31.91 is 511% above median its 10-year median of 5.22. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 35.95. The Biotechnology industry median Current Ratio is 3.88. BeBetter Med's value of 31.91 is 722.4% above this industry median. Based on the distribution chart, BeBetter Med ranks #42 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #42 out of 1408 companies for Current Ratio. This places BeBetter Med in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. BeBetter Med's value of 31.91 is 722.4% above this benchmark. Historically, BeBetter Med's own Current Ratio has ranged from 0.73 to 35.95 over the past decade. While the company's 10-year median is 5.22 vs. the industry median of 3.88, BeBetter Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeBetter Med's current Current Ratio of 31.91 is 722.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeBetter Med's current Current Ratio is 31.91, which is 511% above median its own 10-year median of 5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Current Ratio of 31.91. The current Current Ratio is 31.91, which is 511% above median its 10-year median of 5.22 and 722.4% above the Biotechnology industry median of 3.88. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Current Ratio is 31.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
